ReShape Lifesciences Inc. (RSLS)

NASDAQ: RSLS · Real-Time Price · USD
6.01
-0.65 (-9.76%)
At close: May 12, 2025, 4:00 PM
5.86
-0.15 (-2.50%)
After-hours: May 12, 2025, 4:34 PM EDT
-9.76%
Market Cap 2.71M
Revenue (ttm) 8.01M
Net Income (ttm) -7.13M
Shares Out 451.05K
EPS (ttm) -13.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 140,773
Open 5.67
Previous Close 6.66
Day's Range 5.64 - 6.25
52-Week Range 0.30 - 29.00
Beta 2.12
Analysts Hold
Price Target n/a
Earnings Date May 19, 2025

About RSLS

ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual’s comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the les... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Nov 15, 2007
Employees 18
Stock Exchange NASDAQ
Ticker Symbol RSLS
Full Company Profile

Financial Performance

In 2024, ReShape Lifesciences's revenue was $8.01 million, a decrease of -7.74% compared to the previous year's $8.68 million. Losses were -$7.13 million, -37.38% less than in 2023.

Financial Statements

News

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 700 points on Monday.

Other symbols: ORLA
8 hours ago - Benzinga

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board ...

5 days ago - GlobeNewsWire

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation...

10 days ago - GlobeNewsWire

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowab...

14 days ago - GlobeNewsWire

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device Fully Compatibl...

21 days ago - GlobeNewsWire

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

ReShape Lifesciences Inc. (NASDAQ:RSLS) Earnings Highlights and Strategic Business Update Conference April 10, 2025 4:30 PM ET Company Participants Michael Miller - IR, Rx Communications Paul Hickey ...

4 weeks ago - Seeking Alpha

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market

4 weeks ago - GlobeNewsWire

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Significant Reduction in Overall Operating Expenses of 41.9% in 2024, Excluding M&A Related Expenses, Compared to 2023

5 weeks ago - GlobeNewsWire

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ReS...

7 weeks ago - Business Wire

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia

2 months ago - GlobeNewsWire

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

Liaison Medical is Among the Largest Surgical Device Distributors in Canada Liaison Medical is Among the Largest Surgical Device Distributors in Canada

2 months ago - GlobeNewsWire

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

IRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ®  (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, tod...

3 months ago - GlobeNewsWire

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia

3 months ago - GlobeNewsWire

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas St...

6 months ago - Seeking Alpha

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024

6 months ago - GlobeNewsWire

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canad...

6 months ago - GlobeNewsWire

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments fo...

6 months ago - GlobeNewsWire

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Boar...

8 months ago - GlobeNewsWire

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2024 Earnings Conference Call August 15, 2024 4:30 PM ET Company Participants Michael Miller - IR Paul Hickey - President and CEO Thomas Stankovich - CFO Kr...

9 months ago - Seeking Alpha

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024

9 months ago - GlobeNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...

Other symbols: CHUY
10 months ago - GlobeNewsWire

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”

CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large mark...

10 months ago - GlobeNewsWire

ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger

10 months ago - GlobeNewsWire

ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call Transcript

ReShape Lifesciences, Inc. (NASDAQ:RSLS) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relatons Paul Hickey - President, CEO & Director Thoma...

1 year ago - Seeking Alpha